Last $21.53 USD
Change Today +0.74 / 3.56%
Volume 229.3K
SRPT On Other Exchanges
As of 10:17 AM 09/23/14 All times are local (Market data is delayed by at least 15 minutes).

sarepta therapeutics inc (SRPT) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/7/13 - $55.61
52 Week Low
11/13/13 - $12.12
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

sarepta therapeutics inc (SRPT) Details

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. Its lead product candidate is Eteplirsen, an antisense PMO-based therapeutic in clinical development for the treatment of individuals with Duchenne muscular dystrophy. The company is also involved in developing treatments that are in clinical development include AVI-7288 for the treatment of Marburg virus and AVI-7100 for the treatment of influenza. In addition, it focuses on developing preclinical research product candidates for the treatment of other neuromuscular, infectious, and rare diseases. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

146 Employees
Last Reported Date: 03/3/14
Founded in 1980

sarepta therapeutics inc (SRPT) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $580.0K
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $457.2K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $377.7K
Senior Vice President, General Counsel and Co...
Total Annual Compensation: $376.9K
Senior Vice President of Technical Operations
Total Annual Compensation: $320.5K
Compensation as of Fiscal Year 2013.

sarepta therapeutics inc (SRPT) Key Developments

Sarepta Therapeutics, Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-10-2014 02:40 PM

Sarepta Therapeutics, Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-10-2014 02:40 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Christopher Nishan Garabedian, Chief Executive Officer, President and Director.

Sarepta Enters into Partnership with Flagship Biosciences Multi-Year, Multi-Product Partnership for the Development of Automated Quantitative Endpoint Measurements

Sarepta Therapeutics, Inc. and Flagship Biosciences LLC announced a multi-year, multi-product partnership for the development of automated quantitative endpoint measurements in muscular dystrophy to support the advancement of Sarepta's Duchenne muscular dystrophy (DMD) drug pipeline, including its lead candidate, eteplirsen. This newly established collaboration with Flagship demonstrates Sarepta's commitment to enhancing the objective measurement of dystrophin in tissue samples for its growing pipeline of RNA-based therapeutics to treat DMD. The agreement between the companies also further strengthens Flagship Biosciences' leadership role in diagnostic image analysis and digital pathology to support and optimize targeted drug development.

Sarepta Therapeutics, Inc. Presents at Citi's 9th Annual Biotech Conference, Sep-03-2014

Sarepta Therapeutics, Inc. Presents at Citi's 9th Annual Biotech Conference, Sep-03-2014 . Venue: The Mandarin Oriental Boston, 776 Boylston Street, Boston, MA 02119, United States.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SRPT:US $21.53 USD +0.74

SRPT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AstraZeneca PLC 4,362 GBp -216.00
Baxter International Inc $71.92 USD -0.15
Gilead Sciences Inc $105.54 USD +0.07
Hemispherx Biopharma Inc $0.31 USD -0.008
SciClone Pharmaceuticals Inc $7.01 USD +0.08
View Industry Companies

Industry Analysis


Industry Average

Valuation SRPT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 56.1x
Price/Book 3.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 39.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SAREPTA THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at